# Plain-Language Summary

**What is this about?**
Esophageal adenocarcinoma (EAC) is a cancer of the lower food pipe. It is becoming more common in Western countries, and most people are diagnosed late, when it is hard to treat. Helpfully, this cancer usually develops in slow, recognizable steps — a condition called Barrett's esophagus can turn into pre-cancer (dysplasia) and then into cancer — which gives doctors a chance to intervene early.

**What did we do?**
Using only publicly available scientific data and computer methods — no laboratory experiments — we looked for new ways to treat and to prevent this cancer. Today's approved medicines all aim at a small handful of the same targets, so we deliberately searched for promising biology that other programs have largely overlooked.

**What did we find?**
We identified two candidate targets, each aimed at a different stage of the disease:
- **GUCY2C** — a protein found mainly on the surface of gut cells. We propose a medicine that recruits the immune system to attack tumor cells carrying it, for advanced cancer.
- **DKK1** — a protein released by cells that helps cancer develop. We propose a medicine that mops it up, to *slow or prevent* the change from Barrett's esophagus into cancer.

For both targets, we used AI protein-design tools to create brand-new "binder" proteins — small custom-built molecules that latch onto each target. On the computer, these designs look promising, and one (for DKK1) is especially clean and well-behaved.

**How sure are we?**
This is early, computer-based work. Nothing has yet been made or tested in a laboratory, and we are careful to say so throughout. Two big questions remain: whether a GUCY2C medicine can attack the tumor without harming the healthy gut, and whether regulators would accept "reversing pre-cancer" as proof that a prevention medicine works. These questions decide whether each idea can move forward.

**Why does it matter?**
The work offers a fresh, honest starting point for tackling a rising and deadly cancer — including the rare opportunity to stop it before it fully forms — and a transparent recipe that other scientists can reproduce and build on in the lab.